Heart Disease Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Heart Disease Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Fibrosis Therapy
Scientists at Kurume University, Cardiovascular Research Institute release new data on fibrosis therapy
December 28th, 2008
Research findings, 'Long-term treatment with valsartan improved cyclic variation of the myocardial integral backscatter signal and diastolic dysfunction in hypertensive patients: the echocardiographic assessment,' are discussed in a new report. According to a study from Kurume, Japan, "Myocardial fibrosis is the major determinant of diastolic property of the left ventricle (LV). Experimental and clinical studies have suggested that angiotensin receptor blockers attenuate myocardial fibrosis in various heart diseases." "The integrated backscatter signal (IBS) represents a promising ultrasonic method for assessing the characterization of myocardial tissue: cardiac...
Source: Heart Disease Weekly (2008-12-28)
|
